-
公开(公告)号：US20180305465A1
公开(公告)日：2018-10-25
申请号：US15779325
申请日：2016-11-23
Applicant: AMGEN INC. , XENCOR, INC.
Inventor： Jennitte Leann Stevens , Mercedesz Balazs , Olivier Nolan-Stevaux , Gregory Moore , John Desjarlais , Matthew J. Bernett , Seung Y. Chu , Rumana Rashid , Umesh Muchhal
CPC classification number: C07K16/468 , A61K2039/505 , A61P35/00 , C07K16/2809 , C07K16/40 , C07K2317/31 , C07K2317/55 , C07K2317/622 , C07K2317/73 , C07K2317/92
Abstract: The present invention is directed to heterodimeric antibodies that bind CD3 and CD38.
-
公开(公告)号：US09617348B2
公开(公告)日：2017-04-11
申请号：US13860500
申请日：2013-04-10
Applicant: Xencor, Inc.
Inventor： John R. Desjarlais , Seung Y. Chu , Holly M. Horton , Matthew J. Bernett
IPC: A61K39/395 , C07K16/42 , C07K16/46
CPC classification number: C07K16/4291 , A61K2039/505 , A61P37/08 , C07K16/464 , C07K2317/24 , C07K2317/52 , C07K2317/732 , C07K2317/76 , C07K2317/92
Abstract: The present invention relates to immunoglobulins that bind IgE and FcγRIIb with high affinity, said compositions being capable of inhibiting cells that express membrane-anchored IgE. Such compositions are useful for treating IgE-mediated disorders, including allergies and asthma.
-
公开(公告)号：US09540451B2
公开(公告)日：2017-01-10
申请号：US13860484
申请日：2013-04-10
Applicant: Xencor, Inc.
Inventor： John R. Desjarlais , Seung Y. Chu , Holly M. Horton , Matthew J. Bernett
CPC classification number: C07K16/4291 , A61K2039/505 , A61P37/08 , C07K16/464 , C07K2317/24 , C07K2317/52 , C07K2317/732 , C07K2317/76 , C07K2317/92
Abstract: The present invention relates to immunoglobulins that bind IgE and FcγRIIb with high affinity, said compositions being capable of inhibiting cells that express membrane-anchored IgE. Such compositions are useful for treating IgE-mediated disorders, including allergies and asthma.
Abstract translation: 本发明涉及以高亲和力结合IgE和FcγRIIb的免疫球蛋白，所述组合物能够抑制表达膜锚定的IgE的细胞。 这样的组合物可用于治疗IgE介导的病症，包括过敏和哮喘。
-
公开(公告)号：US09266966B2
公开(公告)日：2016-02-23
申请号：US14510054
申请日：2014-10-08
Applicant: Xencor, Inc.
Inventor： John Desjarlais , Seung Y. Chu , Holly M. Horton , Matthew J. Bernett
IPC: A61K39/395 , C07K16/42 , C07K16/46
CPC classification number: C07K16/4291 , A61K2039/505 , A61P37/08 , C07K16/464 , C07K2317/24 , C07K2317/52 , C07K2317/732 , C07K2317/76 , C07K2317/92
Abstract: The present invention relates to immunoglobulins that bind IgE and FcγRIIb with high affinity, said compositions being capable of inhibiting cells that express membrane-anchored IgE. Such compositions are useful for treating IgE-mediated disorders, including allergies and asthma.
-
公开(公告)号：US09221916B2
公开(公告)日：2015-12-29
申请号：US14510037
申请日：2014-10-08
Applicant: Xencor, Inc.
Inventor： John Desjarlais , Seung Y. Chu , Holly M. Horton , Matthew J. Bernett
IPC: A61K39/395 , C07K16/42 , C07K16/46
CPC classification number: C07K16/4291 , A61K2039/505 , A61P37/08 , C07K16/464 , C07K2317/24 , C07K2317/52 , C07K2317/732 , C07K2317/76 , C07K2317/92
Abstract: The present invention relates to immunoglobulins that bind IgE and FcγRIIb with high affinity, said compositions being capable of inhibiting cells that express membrane-anchored IgE. Such compositions are useful for treating IgE-mediated disorders, including allergies and asthma.
Abstract translation: 本发明涉及以高亲和力结合IgE和FcγRIIb的免疫球蛋白，所述组合物能够抑制表达膜锚定的IgE的细胞。 这样的组合物可用于治疗IgE介导的病症，包括过敏和哮喘。
-
Patent Agency Ranking
公开(公告)号：US11739144B2
公开(公告)日：2023-08-29
申请号：US17690702
申请日：2022-03-09
Applicant: Xencor, Inc.
Inventor： Matthew S. Faber , Sung-Hyung Lee , Yoon Kyung Kim , Jing Qi , Kendra N. Avery , Seung Y. Chu , Alex Nisthal , Matthew J. Bernett , John R. Desjarlais , Chad Borchert
CPC classification number: C07K16/28 , A61P35/00 , C07K16/2809 , C07K16/468 , C12N15/63
Abstract: Provided herein are novel CLDN6 binding domains, and anti-CLDN6×anti-CD3 antibodies that include such CLDN6 binding domains. Also provided herein are methods of using such antibodies for the treatment of CLDN6-associated cancers.
-
公开(公告)号：US11566080B2
公开(公告)日：2023-01-31
申请号：US16783032
申请日：2020-02-05
Applicant: Xencor, Inc.
Inventor： John R. Desjarlais , Seung Y. Chu , Holly M. Horton , Matthew J. Bernett
Abstract: The present invention relates to immunoglobulins that bind IgE and FcγRIIb with high affinity, said compositions being capable of inhibiting cells that express membrane-anchored IgE. Such compositions are useful for treating IgE-mediated disorders, including allergies and asthma.
-
公开(公告)号：US11352442B2
公开(公告)日：2022-06-07
申请号：US16660415
申请日：2019-10-22
Applicant: XENCOR, INC.
Inventor： Matthew J. Bernett , Gregory Moore , John Desjarlais , Seung Y. Chu , Rumana Rashid , Umesh Muchhal
Abstract: The present invention is directed to heterodimeric antibodies that bind CD3 and CD38.
-
公开(公告)号：US20180094079A1
公开(公告)日：2018-04-05
申请号：US15786252
申请日：2017-10-17
Applicant: XENCOR, INC.
Inventor： Matthew J. Bernett , Seung Y. Chu , Gregory Moore , John Desjarlais
CPC classification number: C07K16/468 , C07K16/2809 , C07K16/2896 , C07K16/30 , C07K2317/24 , C07K2317/31 , C07K2317/52 , C07K2317/55 , C07K2317/565 , C07K2317/622 , C07K2317/64 , C07K2317/73 , C07K2317/92 , C07K2317/94
Abstract: The invention provides novel heterodimeric proteins including heterodimeric antibodies.
-
公开(公告)号：US20240400675A1
公开(公告)日：2024-12-05
申请号：US18810362
申请日：2024-08-20
Applicant: Xencor, Inc.
Inventor： Matthew S. Faber , Sung-Hyung Lee , Yoon Kyung Kim , Jing Qi , Kendra N. Avery , Seung Y. Chu , Alex Nisthal , Matthew J. Bernett , John R. Desjarlais , Chad Borchert
Abstract: Provided herein are novel CLDN6 binding domains, and anti-CLDN6×anti-CD3 antibodies that include such CLDN6 binding domains. Also provided herein are methods of using such antibodies for the treatment of CLDN6-associated cancers.
-
-
-
-
-
-
-
-
-
Search Results
17
records
(took 0.021 seconds)
